VERTEX PHARMACEUTICALS INC
NASDAQ: VRTX (Vertex Pharmaceuticals Incorpor)
最近更新时间: 12小时之前402.70
3.35 (0.84%)
| 前收盘价格 | 399.35 |
| 收盘价格 | 399.63 |
| 成交量 | 1,014,711 |
| 平均成交量 (3个月) | 1,420,520 |
| 市值 | 103,706,927,104 |
| 预期市盈率 (P/E Forward) | 21.93 |
| 价格/销量 (P/S) | 9.81 |
| 股市价格/股市净资产 (P/B) | 6.63 |
| 52周波幅 | |
| 利润日期 | 3 Feb 2025 - 7 Feb 2025 |
| 营业毛利率 | -4.51% |
| 营业利益率 (TTM) | 40.82% |
| 稀释每股收益 (EPS TTM) | -1.89 |
| 季度收入增长率 (YOY) | 11.60% |
| 季度盈利增长率 (YOY) | 1.00% |
| 总债务/股东权益 (D/E MRQ) | 11.35% |
| 流动比率 (MRQ) | 2.47 |
| 营业现金流 (OCF TTM) | -842.60 M |
| 杠杆自由现金流 (LFCF TTM) | 3.06 B |
| 资产报酬率 (ROA TTM) | 12.05% |
| 股东权益报酬率 (ROE TTM) | -2.98% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Vertex Pharmaceuticals Incorpor | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 2.63 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Core |
| 内部持股比例 | 0.08% |
| 机构持股比例 | 96.12% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Loomis Sayles & Co L P | 30 Sep 2024 | 3,068,214 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 586.00 (UBS, 45.52%) | 购买 |
| 中 | 497.00 (23.42%) | |
| 低 | 408.00 (Canaccord Genuity, 1.32%) | 卖出 |
| 平均值 | 496.56 (23.31%) | |
| 总计 | 10 购买, 5 保留, 1 卖出 | |
| 平均价格@调整类型 | 449.91 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| JP Morgan | 23 Dec 2024 | 500.00 (24.16%) | 购买 | 405.27 |
| 05 Nov 2024 | 503.00 (24.91%) | 购买 | 499.88 | |
| Scotiabank | 23 Dec 2024 | 430.00 (6.78%) | 保留 | 405.27 |
| 05 Nov 2024 | 486.00 (20.69%) | 保留 | 499.88 | |
| Truist Securities | 23 Dec 2024 | 460.00 (14.23%) | 购买 | 405.27 |
| BMO Capital | 20 Dec 2024 | 520.00 (29.13%) | 购买 | 397.27 |
| Barclays | 20 Dec 2024 | 418.00 (3.80%) | 保留 | 397.27 |
| HC Wainwright & Co. | 20 Dec 2024 | 535.00 (32.85%) | 购买 | 397.27 |
| 21 Oct 2024 | 600.00 (48.99%) | 购买 | 478.09 | |
| B of A Securities | 19 Dec 2024 | 522.00 (29.63%) | 购买 | 396.64 |
| 14 Oct 2024 | 541.00 (34.34%) | 购买 | 484.82 | |
| Stifel | 16 Dec 2024 | 494.00 (22.67%) | 保留 | 468.09 |
| Jefferies | 09 Dec 2024 | 550.00 (36.58%) | 购买 | 473.98 |
| Citigroup | 14 Nov 2024 | 575.00 (42.79%) | 购买 | 483.96 |
| Canaccord Genuity | 06 Nov 2024 | 408.00 (1.32%) | 卖出 | 493.64 |
| Cantor Fitzgerald | 05 Nov 2024 | 480.00 (19.20%) | 购买 | 499.88 |
| 08 Oct 2024 | 480.00 (19.20%) | 购买 | 458.94 | |
| Morgan Stanley | 05 Nov 2024 | 476.00 (18.20%) | 保留 | 499.88 |
| RBC Capital | 05 Nov 2024 | 451.00 (11.99%) | 保留 | 499.88 |
| 09 Oct 2024 | 437.00 (8.52%) | 保留 | 467.97 | |
| UBS | 05 Nov 2024 | 586.00 (45.52%) | 购买 | 499.88 |
| 17 Oct 2024 | 562.00 (39.56%) | 购买 | 498.73 | |
| Oppenheimer | 30 Oct 2024 | 540.00 (34.09%) | 购买 | 475.08 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合